Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 3/2016

01-03-2016 | Original Article

miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3

Authors: Rui Li, Jia Liu, Qun Li, Guang Chen, Xiaofang Yu

Published in: Tumor Biology | Issue 3/2016

Login to get access

Abstract

MicroRNA-29a (miR-29a) has been reported to play important roles in tumor initiation, development, and metastasis in various cancers. However, the biological function and potential mechanisms of miR-29a in papillary thyroid carcinoma (PTC) remain unclear. In the present study, we discovered that miR-29a was frequently downregulated in PTC tissues, and its expression was significantly associated with tumor size, TNM stage, and lymph node metastasis. Functional assays showed that overexpression of miR-29a markedly suppressed PTC cell proliferation, migration, and invasion and promoted PTC apoptosis and cell cycle arrest at G0/G1 phase. In vivo, miR-29a overexpression decreased tumor growth in a xenograft mouse model. Luciferase reporter assay showed that miR-29a can directly bind to the 3′ untranslated region (UTR) of AKT3 in PTC cells. Overexpreesion of miR‑29a obviously decreased AKT3 expression, thereby suppressing phosphatidylinositol 3-kinase (PI3K)/AKT pathway activation. We also confirmed that AKT3 expression was increased in PTC tissue and was inversely correlated miR-29a expression in PTC tissues. In addition, downregulation of AKT3 by siRNA mimicked the effects of miR-29a overexpression, and upregulation of AKT3 partially reversed the inhibitory effects of miR-29a. These results suggested that miR-29a could act as a tumor suppressor in PTC by targeting AKT3 and that miR-29a may potentially serve as an anti-tumor agent in the treatment of PTC.
Literature
1.
2.
Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems. Thyroid Off J Am Thyroid Assoc. 2013;23:1401–7.CrossRef
3.
4.
5.
6.
7.
8.
Esquela-Kerscher A, Slack FJ. Oncomirs - micrornas with a role in cancer. Nat Rev Cancer. 2006;6:259–69.CrossRefPubMed
9.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D. Microrna expression profiles classify human cancers. Nature. 2005;435:834–8.CrossRefPubMed
10.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microrna expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006;103:2257–61.CrossRefPubMedPubMedCentral
11.
Wang Y, Zhang X, Li H, Yu J, Ren X. The role of mirna-29 family in cancer. Eur J Cell Biol. 2013;92:123–8.CrossRefPubMed
12.
Cui Y, Su WY, Xing J, Wang YC, Wang P, Chen XY, et al. Mir-29a inhibits cell proliferation and induces cell cycle arrest through the downregulation of p42.3 in human gastric cancer. PLoS One. 2011;6:e25872.CrossRefPubMedPubMedCentral
13.
Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, et al. Micro-rnas mir-29a and mir-330-5p function as tumor suppressors by targeting the muc1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 1853;2015:2392–403.
14.
Li Y, Kong D, Ahmad A, Bao B, Dyson G, Sarkar FH. Epigenetic deregulation of mir-29a and mir-1256 by isoflavone contributes to the inhibition of prostate cancer cell growth and invasion. Epigenetics. 2012;7:940–9.CrossRefPubMedPubMedCentral
15.
Zhong S, Li W, Chen Z, Xu J, Zhao J. Mir-222 and mir-29a contribute to the drug-resistance of breast cancer cells. Gene. 2013;531:8–14.CrossRefPubMed
16.
Qiu F, Sun R, Deng N, Guo T, Cao Y, Yu Y, et al. Mir-29a/b enhances cell migration and invasion in nasopharyngeal carcinoma progression by regulating sparc and col3a1 gene expression. PLoS One. 2015;10:e0120969.CrossRefPubMedPubMedCentral
17.
Zhao D, Jiang X, Yao C, Zhang L, Liu H, Xia H, et al. Heat shock protein 47 regulated by mir-29a to enhance glioma tumor growth and invasion. J Neuro-Oncol. 2014;118:39–47.CrossRef
18.
Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z. Prognostic value of mir-29a expression in pediatric acute myeloid leukemia. Clin Biochem. 2013;46:49–53.CrossRefPubMed
19.
Kang SS, Kwon T, Kwon DY, Do SI. Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem. 1999;274:13085–90.CrossRefPubMed
20.
21.
Chiang CH, Hou MF, Hung WC. Up-regulation of mir-182 by beta-catenin in breast cancer increases tumorigenicity and invasiveness by targeting the matrix metalloproteinase inhibitor reck. Biochim Biophys Acta. 1830;2013:3067–76.
22.
Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, et al. Micrornas (mir)-221 and mir-222, both overexpressed in human thyroid papillary carcinomas, regulate p27kip1 protein levels and cell cycle. Endocr-Relat Cancer. 2007;14:791–8.CrossRefPubMed
23.
Mardente S, Mari E, Consorti F, Di Gioia C, Negri R, Etna M, et al. Hmgb1 induces the overexpression of mir-222 and mir-221 and increases growth and motility in papillary thyroid cancer cells. Oncol Rep. 2012;28:2285–9.PubMed
24.
Zhang X, Li M, Zuo K, Li D, Ye M, Ding L, et al. Upregulated mir-155 in papillary thyroid carcinoma promotes tumor growth by targeting apc and activating wnt/beta-catenin signaling. J Clin Endocrinol Metab. 2013;98:E1305–13.CrossRefPubMed
25.
Ma Y, Qin H, Cui Y. Mir-34a targets gas1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via pi3k/akt/bad pathway. Biochem Biophys Res Commun. 2013;441:958–63.CrossRefPubMed
26.
Liu L, Wang J, Li X, Ma J, Shi C, Zhu H, et al. Mir-204-5p suppresses cell proliferation by inhibiting igfbp5 in papillary thyroid carcinoma. Biochem Biophys Res Commun. 2015;457:621–6.CrossRefPubMed
27.
Gu L, Sun W. Mir-539 inhibits thyroid cancer cell migration and invasion by directly targeting CARMA1. Biochem Biophys Res Commun. 2015;464: 1128–33.
28.
Guan H, Liang W, Xie Z, Li H, Liu J, Liu L, et al. Down-regulation of mir-144 promotes thyroid cancer cell invasion by targeting zeb1 and zeb2. Endocrine. 2015;48:566–74.CrossRefPubMed
29.
Jiang H, Zhang G, Wu JH, Jiang CP. Diverse roles of mir-29 in cancer (review). Oncol Rep. 2014;31:1509–16.PubMed
30.
Amodio N, Rossi M, Raimondi L, Pitari MR, Botta C, Tagliaferri P, et al. Mir-29s: a family of epi-mirnas with therapeutic implications in hematologic malignancies. Oncotarget. 2015;6:12837–61.CrossRefPubMedPubMedCentral
31.
Rostas 3rd JW, Pruitt HC, Metge BJ, Mitra A, Bailey SK, Bae S, et al. Microrna-29 negatively regulates emt regulator n-myc interactor in breast cancer. Mol Cancer. 2014;13:200.CrossRefPubMedPubMedCentral
32.
Nishikawa R, Goto Y, Kojima S, Enokida H, Chiyomaru T, Kinoshita T, et al. Tumor-suppressive microrna-29s inhibit cancer cell migration and invasion via targeting lamc1 in prostate cancer. Int J Oncol. 2014;45:401–10.PubMed
33.
Tan M, Wu J, Cai Y. Suppression of wnt signaling by the mir-29 family is mediated by demethylation of wif-1 in non-small-cell lung cancer. Biochem Biophys Res Commun. 2013;438:673–9.CrossRefPubMed
34.
Hers I, Vincent EE, Tavare JM. Akt signalling in health and disease. Cell Signal. 2011;23:1515–27.CrossRefPubMed
35.
Guo H, German P, Bai S, Barnes S, Guo W, Qi X, et al. The pi3k/akt pathway and renal cell carcinoma. J Genet Genomics = Yi Chuan Xue Bao. 2015;42:343–53.CrossRefPubMed
36.
Xia P, Xu XY. Pi3k/akt/mtor signaling pathway in cancer stem cells: from basic research to clinical application. Am J Cancer Res. 2015;5:1602–9.PubMedPubMedCentral
37.
Petrulea MS, Plantinga TS, Smit JW, Georgescu CE, Netea-Maier RT. Pi3k/akt/mtor: a promising therapeutic target for non-medullary thyroid carcinoma. Cancer Treat Rev. 2015;41:707–13.
38.
Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/akt pathway in thyroid cancer. Thyroid Off J Am Thyroid Assoc. 2010;20:697–706.CrossRef
Metadata
Title
miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3
Authors
Rui Li
Jia Liu
Qun Li
Guang Chen
Xiaofang Yu
Publication date
01-03-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4165-9

Other articles of this Issue 3/2016

Tumor Biology 3/2016 Go to the issue

Original Article

Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression

Review

E2F1: a promising regulator in ovarian carcinoma

Original Article

Leu/Val SNP polymorphism of CYP1B1 and risk of uterine leiomyoma in a Black population

Original Article

FGF18 as a potential biomarker in serous and mucinous ovarian tumors

Original Article

Repression of PES1 expression inhibits growth of gastric cancer

Original Article

Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits